LISTEN LIVE: Marketplace

Advertisement

 

Cambridge Biotech Company Claims Breakthrough On New Class Of 'Gene-Silencing' Drugs04:37
Download

Play
This article is more than 4 years old.

Stock in the Cambridge pharmaceutical company, Alnylam, is soaring due to expectations it may have successfully tested a so-called "RNAI" drug that could treat a rare malfunction of the nervous system. Luke Timmerman, who writes the bio-tech newsletter "The Timmerman Report," joined Morning Edition.

This segment aired on September 22, 2017.

Bob Oakes Twitter Senior Correspondent
Bob Oakes is a senior correspondent in the WBUR newsroom, a role he took on in 2021 after nearly three decades hosting WBUR's Morning Edition.

More…

Advertisement

 

Advertisement

 
Play
Listen Live
/00:00
Close